Last reviewed · How we verify
AUT00063
At a glance
| Generic name | AUT00063 |
|---|---|
| Also known as | Experimental |
| Sponsor | Autifony Therapeutics Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss (PHASE2)
- Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire) (PHASE2)
- Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AUT00063 CI brief — competitive landscape report
- AUT00063 updates RSS · CI watch RSS
- Autifony Therapeutics Limited portfolio CI